INT121310

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 1.78
Pain Relevance 0.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (Ercc1) chromosome organization (Ercc1) nucleus (Ercc1)
cytoplasm (Ercc1)
Ercc1 (Mus musculus)
Pain Link Frequency Relevance Heat
Bile 24 84.52 Quite High
palliative 5 58.24 Quite High
Disease Link Frequency Relevance Heat
Biliary Cancer 40 90.84 High High
Immunotherapy Of Cancer 2 81.88 Quite High
Bile Duct Neoplasms 22 78.40 Quite High
Disease 14 77.32 Quite High
Cancer 100 69.56 Quite High
Klatskin's Tumor 56 53.84 Quite High
Prostate Cancer 1 50.00 Quite Low
Reprotox - General 1 1 36.12 Quite Low
Gallbladder Neoplasms 12 26.00 Quite Low
Recurrence 54 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
During this period, additional irradiation fails to induce XRCC1, ERCC1, or additional TGF alpha release.


Positive_regulation (induce) of ERCC1
1) Confidence 0.45 Published 2004 Journal Clin. Cancer Res. Section Body Doc Link 15355899 Disease Relevance 0 Pain Relevance 0
Overexpression of the excision repair cross-complementation group 1 (ERCC1) gene, which is crucial in the repair of cisplatin-induced DNA adducts, has been reported to negatively influence to effectiveness of cisplatin-based chemotherapy [4].
Positive_regulation (Overexpression) of ERCC1
2) Confidence 0.44 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2974735 Disease Relevance 0.89 Pain Relevance 0.21
Overexpression of the excision repair cross-complementation group 1 (ERCC1) gene, which is crucial in the repair of cisplatin-induced DNA adducts, has been reported to negatively influence to effectiveness of cisplatin-based chemotherapy [4].
Positive_regulation (Overexpression) of cross-complementation group 1
3) Confidence 0.38 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2974735 Disease Relevance 0.89 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox